Skip to main content

Table 1 Characteristics of the included studies

From: Intravitreal dexamethasone implants versus intravitreal anti-VEGF treatment in treating patients with retinal vein occlusion: a meta-analysis

Study

Year

Country

Type

Disease

Participant number

Intervention details

Number of treatment

Age

Sex number

BCVA at baseline

CST at baseline

Follow up duration

Bandello

2018

France, Germany, Israel, Italy, Spain, and the United Kingdom

RCT

BRVO

Total = 307 n(IVR) = 153 n(DEX) = 154

IVR: 0.5 mg monthly given for 5 consecutive months than PRN

DEX: 0.7 mg Ozurdox injection at month 1 and 5; PRN on month 10 or 11

IVR: 8.0 DEX: 2.5

IVR: 65.5 ± 12.0 DEX: 68.4 ± 10.6

IVR: M: 87; F: 67 DEX: M: 92; F: 61

IVR: 59.2 ± 10.9 DEX: 56.6 ± 10.9

IVR: 544 ± 168 DEX: 547 ± 163

12

Feltgen

2018

German

RCT

BRVO

Total = 92 n(IVR) = 52 n(DEX) = 40

IVR: 0.5 mg PRN injection

DEX: 0.7 mg Ozurdox 1 dose given at the initial treatment or later; time interval of PRN is at least 5 months

IVR: 4.46 ± 2.09 DEX: 0.40 ± 0.50

IVR: 64.5 ± 9.7 DEX: 64.6 ± 9.9

IVR: M: 18; F: 34 DEX: M: 22; F: 18

IVR: 56.8 ± 10.0 DEX: 58.3 ± 10.8

IVR: 563.3 ± 170.0 DEX: 547.3 ± 178.9

6

Feltgen

2018

German

RCT

CRVO

Total = 83 n(IVR) = 61 n(DEX) = 22

IVR: 0.5 mg PRN injection

DEX: 0.7 mg Ozurdox 1 dose given at the initial treatment or later; time interval of PRN is at least 5 months

IVR: 3.92 ± 2.64 DEX: 0.45 ± 0.51

IVR: 66.6 ± 10.1 DEX: 61.1 ± 11.0

IVR: M: 31; F: 30 DEX: M: 30; F: 8

IVR: 54.1 ± 15.8 DEX: 53.2 ± 16.1

IVR: 698.8 ± 228.6 DEX: 721.2 ± 231.1

6

Hattenbach

2018

Germany, Great Britain, the Czech Republic, Poland and Hungary

RCT

BRVO

Total = 244 n(IVR) = 126 n(DEX) = 118

IVR: 0.5 mg monthly given for 3 consecutive months than PRN DEX: 0.7 mg Ozurdox given at the initial treatment and monthly shame PRN injection

IVR: 4.71 DEX: 1

N/A

N/A

N/A

N/A

6

Hoerauf

2016

Germany, Great Britain, Poland, and Hungary

RCT

CRVO

Total = 243 n(IVR) = 124 n(DEX) = 119

IVR: 0.5 mg monthly given for 3 consecutive months than PRN DEX: 0.7 mg Ozurdox given at the initial treatment and monthly shame PRN injection

IVR: 4.52 DEX: 1

IVR: 65.3 ± 11.4 DEX: 66.9 ± 12.4

IVR: M: 72; F: 52 DEX: M: 73; F: 46

IVR: 51.7 ± 16.5 DEX: 51.5 ± 15.6

IVR: 723.8 ± 245.9 DEX: 705.2 ± 231.1

6